Simone N. Cesaro
Expertise in
34
conditions

Simone N. Cesaro

Policlinico GB Rossi
Verona, IT 
Expertise in
34
conditions
Policlinico GB Rossi
Verona, IT 

Overview

Simone Cesaro practices in Verona, Italy. Ms. Cesaro is highly rated in 34 conditions, according to our data. Her top areas of expertise are Shwachman-Diamond Syndrome, Infantile Neutropenia, Hemophagocytic Lymphohistiocytosis, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 302 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Policlinico GB Rossi
Verona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective, Multicenter Survey of Cytomegalovirus (CMV) and Other Herpesviruses Infections and Diseases in Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Recipients.
A Prospective, Multicenter Survey of Cytomegalovirus (CMV) and Other Herpesviruses Infections and Diseases in Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Recipients.
Enrollment Status: Completed
Publish Date: January 06, 2025
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2024
Intervention Type: Drug
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
Enrollment Status: Completed
Publish Date: October 16, 2019
View 5 Less Clinical Trials

302 Total Publications

Erratum to: "Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study".
Erratum to: "Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study".
Journal: Haematologica
Published: November 01, 2025

Frequently Asked Questions about Simone N. Cesaro

Is Simone N. Cesaro a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Simone N. Cesaro is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Simone N. Cesaro participate in research or clinical trials?

Yes. Simone N. Cesaro has published 302 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Simone N. Cesaro's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cesaro's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 18 Advanced Conditions
View All 65 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile